SEP 15 VRBPAC

Background Analysis: US FDA Advisory Committee to Review Novartis’ FLUAD – SEP 15, 2015 (VRBPAC)

The US FDA has scheduled a Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting for Tuesday, September 15, 2015 to discuss and make recommendations on the safety and immunogenicity of Seasonal Trivalent Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59 (FLUAD) manufactured by Novartis.

See the SAC Tracker report